[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymphoid-leukemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymphoid-leukemia":38},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,61,95],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":60},"100560657","phase-2-repurposing-riluzole-for-cancer-related-cognitive-impairment-a-pilot-trial-100560657",false,"NCT06580002","Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial","Repurposing Riluzole for Augmenting Brain-Derived Neuropathic Factor (BDNF) Levels and Cognitive Function in Patients Experiencing Cancer-Related Cognitive Impairment: An Interventional Pilot Clinical Trial","Inclusion Criteria:\n\n1. Cohort-specific inclusion for male and female patients.\n\n   a. Cohort A (no prior cranial radiation) i. Diagnosed with one of the following:\n   * Breast cancer exposed to treatment including chemotherapy, radiotherapy, surgery and\u002For other breast cancer interventions.\n   * Non-breast cancer patients exposed to anthracyclines- or platinum-containing chemotherapy within the past 3 years.\n   * Non-breast cancer patients exposed to other anticancer therapies within the past 3 years.\n\n     b. Cohort B (prior cranial radiation)\n   * Previously received radiotherapy or radiosurgery to the brain for benign, malignant, or metastatic tumors.\n   * Life expectancy \\> 6 months\n2. Washout from investigational and conventional interventions is up to the discretion of the investigator. Concurrent participation in another intervention is allowable if judged by the Principal Investigator that this would not be scientifically or medically incompatible with this study.\n3. ≥18 years of age\n4. Perceived by patient or investigator that cognitive function has worsened since receipt of cranial radiation or cancer treatment.\n5. Able to provide informed consent.\n6. Literacy in English, Chinese, Korean, Vietnamese, or Spanish, to complete the questionnaires.\n7. Patients must agree to complete and be able to complete the questionnaires and computerized assessments used to measure functional outcomes.\n\n   * Note: Patients who have visual impairment or have degenerative conditions (e.g. Parkinsons's disease, etc.) can participate if they cannot complete computerized assessments, as long as they can still complete the questionnaires with assistance.\n\nExclusion Criteria:\n\n1. Cohort-specific exclusion for male and female patients:\n\n   1. Cohort A (no prior cranial radiation)\n\n      * History of or current presence of primary brain tumors or brain metastases.\n   2. Cohort B (prior cranial radiation)\n\n      * Diagnosed with high grade glioma.\n2. Unwilling to undergo neuropsychological assessments necessary for the study.\n3. Women who are breastfeeding, pregnant or are planning to get pregnant during the study period. Persons of child-bearing potential (POCBP) must have a negative pregnancy test at screening if there is suspicion of pregnancy.\n\n   a. Female patients who are considered not to be of childbearing potential must have a history of being postmenopausal (with a minimum of 1 year without menses), tubal ligation, or hysterectomy.\n4. History of suspected hypersensitivity to riluzole or to any of its excipients.\n5. Patients taking or planned to take medications\u002Fsubstances with potential drug-drug interactions: pixantrone, current smoker (defined as having smoked within the last month), abametapir, cannabis, capmatinib, lapatinib, methotrexate, and levoketoconazole.\n6. Hepatic impairment as indicated by: AST or ALT ≥ 3x upper limit normal (ULN)\n7. Have serious pre-existing medical conditions that, in the judgment of the investigator, would preclude participation in this study.","ALL","18 Years",{"count":19,"type":20},75,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels in cancer survivors (recently completing prior treatment regimens) or patients who have received whole brain radiation for benign or malignant tumors with cancer related cognitive impairment.",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47],"Breast Cancer","Sarcoma","Gastric Cancer","Lung Cancer","Head and Neck Cancer","Colorectal Cancer","Ovarian Cancer","Liver Cancer","Genitourinary Cancer","Gynecologic Cancer","Urinary Bladder Cancer","Leukemia","Lymphoid Leukemia","Myeloma Multiple","Prostate Cancer","Pancreas Cancer","Non-hodgkin Lymphoma","Hodgkin Lymphoma","Brain Cancer","Melanoma","Mycosis Fungoides","Kidney Cancer","RECRUITING","2026-07-11",{"date":51,"type":52},"2026-07-14","ACTUAL",{"date":54,"type":52},"2024-12-02",{"date":56,"type":20},"2027-12",{"name":58,"class":59},"University of California, Irvine","OTHER",1,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":16,"minAge":69,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":21,"phases":72,"briefSummary":74,"conditions":75,"keywords":81,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":60},"100615412","halt-aging-in-survivors-of-blood-cancers-100615412","NCT07292272","Halt Aging in Survivors of Blood Cancers","Halt Aging in Survivors of Blood Cancers: the HALTAging-1 Study","HALTAging-1","Inclusion Criteria:\n\n1. Age ≥50 years\n2. A history of hematological malignancy\n3. Participants must be able to and willingly give informed consent\n\nExclusion Criteria:\n\n1. Patients receiving intensive induction or consolidation chemotherapy. Maintenance chemotherapy, or lower-intensity chemotherapy for an indolent hematological malignancy is allowed.\n2. Neurodegenerative disease (e.g. Alzheimer's dementia), stroke, or uncontrolled psychotic disorders (e.g. schizophrenia or bipolar disorder) in the past 3 months if those disorders are considered significant enough to impair participation in the study.\n3. Illnesses such as clinical evidence of decompensated heart failure, unstable angina, or orthopedic or neuromuscular disorders that could limit safe participation in aerobic exercise.\n4. Cardiopulmonary exercise test results that preclude safe exercise (e.g., life-threatening arrhythmia, balance difficulties, peak VO2 \\\u003C10 ml\u002Fkg\u002Fmin).\n5. Estimated life expectancy of less than 6 months (that precludes assessment of study primary endpoint).\n6. Self-reported pregnancy or the possibility of pregnancy.\n7. Participants who do not plan to follow up at the participating center.","50 Years",{"count":71,"type":20},180,[73],"NA","Older survivors of blood cancer are at a high risk of accelerated biological aging, which increases their risk of developing multiple aging-related conditions. Whereas physical exercise can improve overall health, older cancer survivors do not meet the recommended physical activity, highlighting the need to develop behavioral interventions to increase adherence. Several other knowledge gaps exist to implement exercise interventions in older survivors of blood cancer; the dose and duration of exercise necessary to slow biological aging in older blood cancer survivors remain unknown. To bridge these gaps in knowledge, we have designed a Phase 2 randomized control trial to test the effects of behavioral and exercise interventions on various outcomes.",[76,37,38,77,78,79,42,80],"Hematological Malignancy","Multiple Myeloma","Myeloid Leukemia","Monocytic Leukemia","Other Hematologic Condition",[43,37,38,77,78,79,42,80,82,83,84,85],"Epigenetic clock","Biological aging","Quality of life","Blood cancer survivors","2026-06-29",{"date":88,"type":52},"2026-07-01",{"date":90,"type":52},"2026-04-09",{"date":92,"type":20},"2033-03-25",{"name":94,"class":59},"University of Nebraska",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":104,"phases":4,"briefSummary":105,"conditions":106,"keywords":107,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":119},"100505739","outcomes-in-pediatric-and-young-adult-b-cell-malignancies-after-commercially-available-immunotherapy-100505739","NCT05865301","Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy","Inclusion Criteria (Arm A)\n\n\\* Disease Status - B cell precursor acute lymphoblastic leukemia (ALL) or B cell lymphoma\n\nWho either:\n\n* Experienced refractory or relapsed disease, treated with standard chemotherapy, without immunotherapy treatment.\n\nOR\n\n* Previously undergone standard of care immunotherapy with FDA approved therapies, such as Kymriah™ (CTL019, tisagenlecleucel), blinatumomab or\n\n  * Age: Greater than or equal to 0 year of age and less than or equal to 26 years of age.\n\nInclusion Criteria (Arm B)\n\n* Disease Status - B cell precursor acute lymphoblastic leukemia (ALL) or B cell lymphoma\n* Age: Greater than or equal to 0 year of age and less than or equal to 26 years of age\n* Patients who are either:\n\n  * Undergoing evaluation for leukapheresis for planned standard of care tisagenlecleucel therapy, or planned for therapy with blinatumomab or inotuzumab. (Patients who received prior tisagenlecleucel, blinatumomab or inotuzumab on an established clinical trial and are now scheduled for commercial CAR, blinatumomab or inotuzumab therapy are also eligible) Or\n  * Experienced refractory or relapsed B cell precursor acute lymphoblastic leukemia (ALL) or B cell lymphoma\n* Ability to give informed consent. All subjects ≥ 18 years of age must be able to give informed consent or have legal authorized representative (LAR) (i.e. parent or guardian) to consent, if not in capacity to give consent independently. For subjects \\\u003C18 years old their LAR must give informed consent. Pediatric subjects will be included in age appropriate discussion and written assent will be obtained for those \\> 7 years of age, when appropriate, according to institutional procedures.","26 Years",{"count":103,"type":20},500,"OBSERVATIONAL","To use a consistent and standardized platform to retrospectively and prospectively study children and young adults with B cell malignancies receiving Immunotherapy, blinatumomab and\u002For inotuzumab ozogamicin.",[38],[108,109],"PRWCC","Foresight","2026-06-02",{"date":112,"type":52},"2026-06-04",{"date":114,"type":52},"2023-06-29",{"date":116,"type":20},"2038-12-31",{"name":118,"class":59},"Stanford University",22]